Option Care Health (OPCH) 10-Q 3 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-11993
Entity Registrant Name	OPTION CARE HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	05-0489664
Entity Address, Address Line One	3000 Lakeside Dr.
Entity Address, Address Line Two	Suite 300N,
Entity Address, City or Town	Bannockburn,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	312
Local Phone Number	940-2443
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	OPCH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		186,758,939
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 140,047	$ 67,056
Accounts receivable, net	320,920	324,416
Inventories	155,478	115,876
Prepaid expenses and other current assets	60,030	51,306
Total current assets	676,475	558,654
NONCURRENT ASSETS:
Property and equipment, net	113,017	133,198
Operating lease right-of-use asset	70,344	63,502
Intangible assets, net	359,766	385,910
Goodwill	1,428,610	1,425,542
Other noncurrent assets	20,278	22,741
Total noncurrent assets	1,992,015	2,030,893
TOTAL ASSETS	2,668,490	2,589,547
CURRENT LIABILITIES:
Accounts payable	290,206	221,060
Accrued compensation and employee benefits	51,226	45,765
Accrued expenses and other current liabilities	63,239	33,538
Current portion of operating lease liability	19,252	20,391
Current portion of long-term debt	9,250	9,250
Total current liabilities	433,173	330,004
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion	1,162,836	1,277,246
Operating lease liability, net of current portion	67,471	58,242
Deferred income taxes	3,040	2,143
Other noncurrent liabilities	8,474	15,085
Total noncurrent liabilities	1,241,821	1,352,716
Total liabilities	1,674,994	1,682,720
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September 30, 2020 and December 31, 2019, respectively	0	0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 187,141,475 shares issued and 186,757,753 shares outstanding as of September 30, 2020; 176,975,628 shares issued and 176,591,907 shares outstanding as of December 31, 2019	19	18
Treasury stock; 383,722 shares outstanding, at cost, as of September 30, 2020 and December 31, 2019, respectively	(2,403)	(2,403)
Paid-in capital	1,128,979	1,008,362
Accumulated deficit	(117,870)	(91,955)
Accumulated other comprehensive loss	(15,229)	(7,195)
Total stockholders’ equity	993,496	906,827
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,668,490	$ 2,589,547

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	12,500,000	12,500,000
Preferred stock, shares, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares, issued (in shares)	187,141,475	176,975,628
Common stock, shares, outstanding (in shares)	186,757,753	176,591,907
Treasury stock, at cost (in shares)	383,722	383,722

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
NET REVENUE	$ 781,609	$ 615,880	$ 2,227,897	$ 1,589,638
COST OF REVENUE	607,456	478,107	1,729,395	1,252,281
GROSS PROFIT	174,153	137,773	498,502	337,357
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	123,000	133,475	377,198	315,815
Depreciation and amortization expense	16,597	16,023	54,892	36,142
Total operating expenses	139,597	149,498	432,090	351,957
OPERATING INCOME (LOSS)	34,556	(11,725)	66,412	(14,600)
OTHER INCOME (EXPENSE):
Interest expense, net	(24,583)	(21,509)	(84,102)	(44,117)
Equity in earnings of joint ventures	790	826	2,364	2,018
Other, net	(8,344)	(6,810)	(8,322)	(6,679)
Total other expense	(32,137)	(27,493)	(90,060)	(48,778)
INCOME (LOSS) BEFORE INCOME TAXES	2,419	(39,218)	(23,648)	(63,378)
INCOME TAX EXPENSE (BENEFIT)	756	3,576	2,267	(3,269)
NET INCOME (LOSS)	1,663	(42,794)	(25,915)	(60,109)
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:
Change in unrealized gains (losses) on cash flow hedges, net of income tax expense (benefit) of $0, $32, $0 and $259, respectively	4,022	(8,249)	(8,034)	(8,727)
OTHER COMPREHENSIVE INCOME (LOSS)	4,022	(8,249)	(8,034)	(8,727)
NET COMPREHENSIVE INCOME (LOSS)	$ 5,685	$ (51,043)	$ (33,949)	$ (68,836)
EARNINGS (LOSS) PER COMMON SHARE:
Earnings (loss) per share, basic (in dollars per share)	$ 0.01	$ (0.26)	$ (0.14)	$ (0.40)
Earnings (loss) per share, diluted (in dollars per share)	$ 0.01	$ (0.26)	$ (0.14)	$ (0.40)
Weighted average common shares outstanding, basic (in shares)	184,232	162,894	179,220	149,448
Weighted average common shares outstanding, diluted (in shares)	184,822	162,894	179,220	149,448

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Income taxes on unrealized gains (losses) on cash flow hedges	$ 0	$ 32	$ 0	$ 259

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (25,915)	$ (60,109)
Adjustments to reconcile net loss to net cash provided by operations:
Depreciation and amortization expense	60,054	38,997
Non-cash operating lease costs	13,020	15,246
Deferred income taxes - net	897	(5,252)
Loss on extinguishment of debt	8,349	5,469
Amortization of deferred financing costs	4,153	3,057
Paid-in-kind interest capitalized as principal	7,525	0
Loss on interest rate swaps upon discontinuing hedge accounting	3,746	0
Equity in earnings of joint ventures	(2,364)	(2,018)
Stock-based incentive compensation expense	2,588	3,898
Other adjustments	1,589	1,046
Changes in operating assets and liabilities:
Accounts receivable, net	3,496	71,029
Inventories	(39,602)	(6,212)
Prepaid expenses and other current assets	(8,724)	1,447
Accounts payable	66,508	(36,157)
Accrued compensation and employee benefits	5,461	5,312
Accrued expenses and other current liabilities	16,768	(3,846)
Operating lease liabilities	(11,976)	(11,922)
Other noncurrent assets and liabilities	(3,845)	(3,415)
Net cash provided by operating activities	101,728	16,570
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(12,871)	(13,150)
Other investing cash flows	541	636
Business acquisitions, net of cash acquired	0	(700,170)
Net cash used in investing activities	(12,330)	(712,684)
CASH FLOWS FROM FINANCING ACTIVITIES:
Redemptions to related parties	0	(2,000)
Sale of management notes receivable	0	1,310
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(904)	(2,497)
Proceeds from debt	0	981,050
Repayments of debt principal	(6,937)	(2,075)
Retirement of debt obligations	(125,000)	(226,738)
Deferred financing costs	0	(36,538)
Net proceeds from issuance of common stock	118,934	0
Other financing cash flows	(2,500)	0
Net cash (used in) provided by financing activities	(16,407)	712,512
NET INCREASE IN CASH AND CASH EQUIVALENTS	72,991	16,398
Cash and cash equivalents - beginning of the period	67,056	36,391
CASH AND CASH EQUIVALENTS - END OF PERIOD	140,047	52,789
Supplemental disclosure of cash flow information:
Cash paid for interest	73,224	35,531
Cash paid for income taxes	2,373	1,617
Cash paid for operating leases	$ 19,941	$ 15,248

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2018	$ 602,825	$ 0	$ 14	$ 0	$ 619,621	$ (1,619)	$ (16,035)	$ 844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(21)					(21)
Stockholders' redemption	(2,000)				(2,000)
Stock-based incentive compensation	584				584
Net loss	(3,712)						(3,712)
Other comprehensive income (loss)	(505)							(505)
Equity, ending balance at Mar. 31, 2019	597,171	0	14	0	618,205	(1,640)	(19,747)	339
Equity, beginning balance at Dec. 31, 2018	602,825	0	14	0	619,621	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(60,109)
Other comprehensive income (loss)	(8,727)
Equity, ending balance at Sep. 30, 2019	921,682	0	18	(2,399)	1,008,090	0	(76,144)	(7,883)
Equity, beginning balance at Mar. 31, 2019	597,171	0	14	0	618,205	(1,640)	(19,747)	339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(18)					(18)
Stockholders' redemption	0				(371)	371
Stock-based incentive compensation	569				569
Net loss	(13,603)						(13,603)
Other comprehensive income (loss)	27							27
Equity, ending balance at Jun. 30, 2019	584,146	0	14	0	618,403	(1,287)	(33,350)	366
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(23)					(23)
Stock-based incentive compensation	2,745				2,745
Repayment of management notes receivable	1,310					1,310
Purchase of BioScrip, Inc.	387,044		4		387,040
Exercise of stock options, vesting of restricted stock and related tax withholdings	(2,497)			(2,399)	(98)
Net loss	(42,794)						(42,794)
Other comprehensive income (loss)	(8,249)							(8,249)
Equity, ending balance at Sep. 30, 2019	921,682	0	18	(2,399)	1,008,090	0	(76,144)	(7,883)
Equity, beginning balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	0	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	757				757
Exercise of stock options, vesting of restricted stock and related tax withholdings	(549)				(549)
Net loss	(19,910)						(19,910)
Other comprehensive income (loss)	(16,632)							(16,632)
Equity, ending balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	0	(111,865)	(23,827)
Equity, beginning balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	0	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(25,915)
Other comprehensive income (loss)	(8,034)
Equity, ending balance at Sep. 30, 2020	993,496	0	19	(2,403)	1,128,979	0	(117,870)	(15,229)
Equity, beginning balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	0	(111,865)	(23,827)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	661				661
Exercise of stock options, vesting of restricted stock and related tax withholdings	(96)				(96)
Net loss	(7,668)						(7,668)
Other comprehensive income (loss)	4,576							4,576
Equity, ending balance at Jun. 30, 2020	867,966	0	18	(2,403)	1,009,135	0	(119,533)	(19,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	1,170				1,170
Exercise of stock options, vesting of restricted stock and related tax withholdings	(259)				(259)
Net proceeds from the issuance of common stock	118,934		1		118,933
Net loss	1,663						1,663
Other comprehensive income (loss)	4,022							4,022
Equity, ending balance at Sep. 30, 2020	$ 993,496	$ 0	$ 19	$ (2,403)	$ 1,128,979	$ 0	$ (117,870)	$ (15,229)

NATURE OF OPERATIONS AND PRESEN

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Presentation of Financial Statements	NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Corporate Organization and Business — HC Group Holdings II, Inc. (“HC II”) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (“HC I”). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (“Option Care”). On March 14, 2019, HC I and HC II entered into a definitive agreement (the “Merger Agreement”) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the “Merger”) was completed on August 6, 2019 (the “Merger Date”). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer. Under the terms of the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into 135,565,392 shares of BioScrip common stock, par value $0.0001 (the “BioScrip common stock”). BioScrip also issued an additional 7,048,357 shares to HC I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which are held in escrow to prevent dilution related to potential additional vesting on certain share-based instruments. See Note 15, Stockholders’ Equity , for additional discussion of these shares held in escrow. In conjunction with the Merger, holders of BioScrip preferred shares and certain warrants received 864,603 additional shares of BioScrip common stock and preferred shares were repurchased for $125.8 million of cash. In addition, all legacy BioScrip debt was settled for $575.0 million. As a result of the Merger, BioScrip’s stockholders held approximately 19.3% of the combined company, and HC I held approximately 80.7% of the combined company. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (“Option Care Health”, or the “Company”). The combined company’s stock is listed on the Nasdaq Global Select Market as of September 30, 2020. See Note 3, Business Acquisitions , for further discussion of the Merger. Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 102 full service pharmacies. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2019 audited consolidated financial statements, including the notes thereto, as presented in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020. Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation. The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the consolidated statements of comprehensive income (loss).

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. In April 2020, the Company received $11.7 million in Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) grant funds from the federal government, which was reflected in the second quarter as a cash inflow from financing activities within other financing cash flows in the unaudited condensed consolidated statements of cash flows. During the third quarter, the Company returned the funds as unused to the federal government, which was reflected as a cash outflow from financing activities within other financing cash flows in the unaudited condensed consolidated statements of cash flows. Equity Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2020 and December 31, 2019, the balance of the investments were $16.6 million and $17.0 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earning of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees are recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The Company’s proportionate share of earnings was $0.8 million and $2.4 million for the three and nine months ended September 30, 2020. The Company’s proportionate share of earnings was $0.8 million and $2.0 million for the three and nine months ended September 30, 2019. Distributions from the investees are treated as cash inflows from operating activities within other adjustments in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2020, the Company received distributions from the investees of $2.3 million and $2.8 million, respectively. During the three and nine months ended September 30, 2019, the Company received distributions from the investees of $0.5 million and $0.5 million, respectively. See Footnote 16, Related-Party Transactions , for discussion of related-party transactions with these investees. Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 16% and 15% for the three and nine months ended September 30, 2020. Revenue related to the Company’s largest payer was approximately 15% and 13% for the three and nine months ended September 30, 2019, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented. For the three and nine months ended September 30, 2020, approximately 16% and 14%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2019, approximately 13% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of September 30, 2020 and December 31, 2019, respectively, approximately 13% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care. For the three and nine months ended September 30, 2020, approximately 71% and 72%, respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the three and nine months ended September 30, 2019, approximately 69% and 72%, respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Although there is uncertainty regarding the COVID-19 pandemic, as of September 30, 2020 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations. Recently-Adopted Accounting Pronouncements — In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held. The Amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity’s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

BUSINESS ACQUISITIONS

BUSINESS ACQUISITIONS	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Business Acquisitions	BUSINESS ACQUISITIONS Merger with BioScrip, Inc. — As discussed in Note 1, Nature of Operations and Presentation of Financial Statements, Option Care merged with BioScrip on August 6, 2019. BioScrip was a national provider of infusion and home care management solutions. The Merger of Option Care and BioScrip into Option Care Health created an expanded national platform and the opportunity to drive economies of scale through procurement savings, facility rationalization and other operating cost savings. The fair value of purchase consideration transferred on the closing date includes the value of the number of shares of the combined company owned by BioScrip shareholders at closing of the Merger, the value of common shares issued to certain warrant and preferred shareholders in conjunction with the Merger, the fair value of stock-based instruments that were vested or earned as of the Merger, and cash payments made in conjunction with the Merger. The fair value per share of BioScrip’s common stock was $2.67 per share. This is the closing price of the BioScrip common stock on August 6, 2019. Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands): Amount Number of BioScrip common shares outstanding at time of the Merger (1) 129,181 Common shares issued to warrant and preferred stockholders at time of the Merger (1) 3,458 Total shares of BioScrip common stock outstanding at time of the Merger (1) 132,639 BioScrip share price as of August 6, 2019 $ 2.67 Fair value of common shares $ 354,146 Fair value of share-based instruments $ 32,898 Cash paid in conjunction with the Merger included in purchase consideration $ 714,957 Fair value of total consideration transferred $ 1,102,001 Less: cash acquired $ 14,787 Fair value of total consideration acquired, net of cash acquired $ 1,087,214 (1) These shares were not adjusted for the one share for four share reverse stock split effective on February 3, 2020. See Note 15, Stockholders’ Equity , for further discussion of the one share for four share reverse stock split. Cash paid in conjunction with the Merger includes payments made for settlement of $575.0 million in legacy BioScrip debt, $125.8 million in existing BioScrip preferred shares, and $14.1 million in legacy BioScrip success-based fees owed to third-party advisors. HC II financed these payments primarily through cash on hand and debt financing. The Company's allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands): Amount Accounts receivable, net (1) $ 96,532 Inventories (2) 19,683 Property and equipment, net (3) 48,732 Intangible assets, net (4) 193,245 Deferred tax assets, net of deferred tax liabilities (5) 26,731 Operating lease right-of-use asset (6) 22,378 Operating lease liability (6) (28,897) Accounts payable (7) (66,668) Other assumed liabilities, net of other acquired assets (7) (20,663) Total acquired identifiable assets and liabilities 291,073 Goodwill (8) 796,141 Total consideration transferred $ 1,087,214 (1) Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio. (2) Inventories are stated at fair value as of the Merger Date. (3) The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised. (4) The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,536 2 Patient referral sources 180,329 20 Licenses 380 1.5 Total intangible assets, net $ 193,245 18.8 The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach. (5) Net deferred tax assets represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. (6) The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the Company. (7) Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the Merger Date. (8) The Merger resulted in $796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger is not expected to be deductible for tax purposes. Assuming BioScrip had been acquired as of January 1, 2018, and the results of BioScrip had been included in operations beginning on January 1, 2018, the unaudited pro forma results of operations for the three and nine months ended September 30, 2019 were net revenue of $690.4 million and $2,034.6 million, respectively, and net loss of $18.7 million and $54.2 million, respectively. The pro forma net loss adjusts for the effect of fair value adjustments related to the Merger, transaction costs and other non-recurring costs directly attributable to the Merger and the impact of the additional debt to finance the Merger. Unaudited pro forma information is not necessarily indicative of the results that actually would have occurred had the Merger been completed on the date indicated or the future operating results.

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2020 and 2019 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Commercial payers $ 644,385 $ 525,927 $ 1,893,105 $ 1,373,481 Government payers 127,435 80,280 308,830 194,875 Patients 9,789 9,673 25,962 21,282 Net revenue $ 781,609 $ 615,880 $ 2,227,897 $ 1,589,638

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES During the three and nine months ended September 30, 2020, the Company recorded tax expense of $0.8 million and $2.3 million, respectively, which represents an effective tax rate of 31.3% and (9.6)%, respectively. During the three and nine months ended September 30, 2019 the Company recorded a tax expense (benefit) of $3.6 million and $(3.3) million, respectively, which represents an effective tax rate of (9.1)% and 5.2%, respectively. The Company maintains a full valuation allowance against all of its net U.S. federal and state deferred tax assets with the exception of $0.6 million of estimated state net operating losses (“NOL”). In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income and tax-planning strategies, in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated. Based on the Company’s full valuation allowance, as noted above, the Company’s tax expense for the three and nine months ended September 30, 2020 of $0.8 million and $2.3 million consists of quarterly tax liabilities attributable to specific state taxing authorities as well as recognized deferred tax expense. The Company recorded no income tax expense or benefit for the three or nine months ended September 30, 2020 and 2019 associated with the tax provisions of the CARES Act.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	EARNINGS (LOSS) PER SHARE The Company presents basic and diluted earnings (loss) per share for its common stock. Basic earnings (loss) per share is calculated by dividing the net income (loss) of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities. As a result of the Merger, which has been accounted for as a reverse merger, all historical per share data and number of shares and equity awards were retroactively adjusted. The earnings (loss) is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended September 30, 2020 includes the effect of shares that would be issued in connection with warrants, stock options and restricted stock awards, as these common stock equivalents are dilutive to the earnings per share recorded in the quarter. The computation of diluted shares for the nine months ended September 30, 2020 and the three and nine months ended September 30, 2019 excludes the effect of these common stock equivalents as their inclusion would be anti-dilutive to the loss per share recorded in those periods. As of September 30, 2020 there were 2,328,120 warrants, 424,878 stock options and 600,483 restricted stock awards outstanding that were excluded from the calculation of earnings (loss) per share for the nine months ended September 30, 2020 as they would be anti-dilutive. As of September 30, 2019, there were 2,987,336 warrants, 657,846 stock options and 109,905 restricted stock awards outstanding that were excluded from the calculation of earnings (loss) per share for the three and nine months ended September 30, 2019 as they would be anti-dilutive. The following table presents the Company’s basic earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) $ 1,663 $ (42,794) $ (25,915) $ (60,109) Denominator: Weighted average number of common shares outstanding 184,232 162,894 179,220 149,448 Earnings (loss) per common share: Earnings (loss) per common share, basic $ 0.01 $ (0.26) $ (0.14) $ (0.40) The following table presents the Company’s diluted earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) $ 1,663 $ (42,794) $ (25,915) $ (60,109) Denominator: Weighted average number of common shares outstanding 184,232 162,894 179,220 149,448 Effect of dilutive securities 590 — — — Weighted average number of common shares outstanding, diluted 184,822 162,894 179,220 149,448 Earnings (loss) per common share: Earnings (loss) per common share, diluted $ 0.01 $ (0.26) $ (0.14) $ (0.40)

LEASES

LEASES	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	LEASES During the three and nine months ended September 30, 2020, the Company incurred operating lease expenses of $7.6 million and $23.0 million, respectively, including short-term lease expense, which were included as a component of selling, general and administrative expense in the unaudited condensed consolidated statements of comprehensive income (loss). During the three and nine months ended September 30, 2019, the Company incurred operating lease expense of $7.4 million and $21.5 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss). As of September 30, 2020, the weighted-average remaining lease term was 6.8 years and the weighted-average discount rate was 5.30%. Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2020 $ 8,688 2021 22,799 2022 17,417 2023 13,698 2024 10,177 Thereafter 36,473 Total lease payments $ 109,252 Less: Interest 22,529 Present value of lease liabilities $ 86,723 During the three and nine months ended September 30, 2019, the Company did not enter into any significant new operating or financing leases. During the three and nine months ended September 30, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow of $20.1 million related to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. As of September 30, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.
Leases	LEASES During the three and nine months ended September 30, 2020, the Company incurred operating lease expenses of $7.6 million and $23.0 million, respectively, including short-term lease expense, which were included as a component of selling, general and administrative expense in the unaudited condensed consolidated statements of comprehensive income (loss). During the three and nine months ended September 30, 2019, the Company incurred operating lease expense of $7.4 million and $21.5 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss). As of September 30, 2020, the weighted-average remaining lease term was 6.8 years and the weighted-average discount rate was 5.30%. Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2020 $ 8,688 2021 22,799 2022 17,417 2023 13,698 2024 10,177 Thereafter 36,473 Total lease payments $ 109,252 Less: Interest 22,529 Present value of lease liabilities $ 86,723 During the three and nine months ended September 30, 2019, the Company did not enter into any significant new operating or financing leases. During the three and nine months ended September 30, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow of $20.1 million related to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. As of September 30, 2020, the Company did not have any significant operating or financing leases that had not yet commenced.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	PROPERTY AND EQUIPMENT Property and equipment was as follows as of September 30, 2020 and December 31, 2019 (in thousands): September 30, 2020 December 31, 2019 Infusion pumps $ 33,368 $ 30,416 Equipment, furniture and other 49,931 51,454 Leasehold improvements 79,828 80,916 Computer software, purchased and internally developed 36,567 34,884 Assets under development 7,284 14,150 206,978 211,820 Less: accumulated depreciation 93,961 78,622 Property and equipment, net $ 113,017 $ 133,198 Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2020 and 2019 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Depreciation expense in cost of revenue $ 1,643 $ 1,384 $ 5,161 $ 2,855 Depreciation expense in operating expenses 7,814 8,522 28,546 18,849 Total depreciation expense $ 9,457 $ 9,906 $ 33,707 $ 21,704

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2020 (in thousands): Balance at December 31, 2019 $ 1,425,542 Purchase accounting adjustments 2,341 Balance at March 31, 2020 $ 1,427,883 Purchase accounting adjustments 727 Balance at June 30, 2020 $ 1,428,610 Changes — Balance at September 30, 2020 $ 1,428,610 Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2019 (in thousands): Balance at December 31, 2018 $ 632,469 Changes — Balance at March 31, 2019 $ 632,469 Changes — Balance at June 30, 2019 $ 632,469 Acquisitions 786,904 Balance at September 30, 2019 $ 1,419,373 The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2020 and December 31, 2019 (in thousands): September 30, 2020 December 31, 2019 Gross intangible assets: Referral sources $ 438,121 $ 438,121 Trademarks/names 44,536 44,536 Other amortizable intangible assets 402 402 Total gross intangible assets 483,059 483,059 Accumulated amortization: Referral sources (103,947) (84,295) Trademarks/names (19,046) (12,748) Other amortizable intangible assets (300) (106) Total accumulated amortization (123,293) (97,149) Total intangible assets, net $ 359,766 $ 385,910 Amortization expense for intangible assets was $8.8 million and $26.3 million for the three and nine months ended September 30, 2020, respectively. Amortization expense for intangible assets was $7.5 million and $17.3 million for the three and nine months ended September 30, 2019, respectively.

INDEBTEDNESS

INDEBTEDNESS	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Indebtedness	INDEBTEDNESS Long-term debt consisted of the following as of September 30, 2020 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 918,063 (7,546) (20,506) 890,011 Second lien notes 294,781 (7,590) (5,116) 282,075 $ 1,212,844 $ (15,136) $ (25,622) 1,172,086 Less: current portion (9,250) Total long-term debt $ 1,162,836 Long-term debt consisted of the following as of December 31, 2019 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 925,000 (8,399) (22,825) 893,776 Second lien notes 412,256 (11,672) (7,864) 392,720 $ 1,337,256 $ (20,071) $ (30,689) 1,286,496 Less: current portion (9,250) Total long-term debt $ 1,277,246 The interest rate on the first lien term loan was 4.65% and 6.20% as of September 30, 2020 and December 31, 2019, respectively. The weighted average interest rate incurred on the first lien term loan was 4.67% and 5.29% for the three and nine months ended September 30, 2020. The weighted average interest rate incurred on the first lien term loan was 6.67% for the period August 6, 2019 through September 30, 2019. The weighted average interest rate incurred on the previous first lien term loan was 6.06% and 6.20% for the three and nine months ended September 30, 2019, respectively, prior to the retirement of the previous credit facilities on August 6, 2019. The interest rate on the second lien notes was 9.00% and 10.66% as of September 30, 2020 and December 31, 2019, respectively. The weighted average interest incurred on the second lien notes was 9.51% and 10.17% for the three and nine months ended September 30, 2020. The weighted average interest rate incurred on the second lien notes was 10.89% for the period August 6, 2019 through September 30, 2019. The weighted average interest incurred on the previous second lien term loan was 11.02% and 11.36% for the three and nine months ended September 30, 2019, respectively, prior to the retirement of the previous credit facilities on August 6, 2019. The Company elected to pay-in-kind (“PIK”) the quarterly interest payment due in August 2020 for the second lien notes, which resulted in the Company capitalizing $7.5 million in interest expense to the principal balance of the second lien term loan on the interest payment date. In connection with the PIK election, the Company was charged an additional 1.00% in interest expense during the quarterly interest period. During the three months ended September 30, 2020, the Company completed a public offering of stock for net proceeds of $118.9 million. Those proceeds, along with additional cash on hand, were used to prepay $125.0 million of the second lien notes, which is reflected as a cash outflow from financing activities in the Company’s unaudited condensed consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $8.3 million, of which $2.5 million related to a prepayment penalty and $5.8 million related to deferred financing fees, which were written off upon extinguishment. The $2.5 million prepayment penalty was reflected as a cash outflow from financing activities in the unaudited condensed consolidated statements of cash flows. See Note 15, Stockholders’ Equity , for further discussion of the public offering. Long-term debt matures as follows (in thousands): Year Ending December 31, Minimum Payments 2020 $ 2,313 2021 9,250 2022 9,250 2023 9,250 2024 9,250 Thereafter 1,173,531 Total 1,212,844 During the three and nine months ended September 30, 2020 and 2019, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments , for further discussion. The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2020 (in thousands): Financial Instrument Carrying Value as of September 30, 2020 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First lien term loan $ 890,011 $ — $ 905,485 $ — Second lien notes 282,075 — — 321,172 Total debt instruments $ 1,172,086 $ — $ 905,485 $ 321,172 The following table sets forth the changes in Level 3 measurements for the three and nine months ended September 30, 2020 (in thousands): Level 3 Measurements Second lien notes fair value as of January 1, 2020 $ 411,119 Change in fair value (71,748) Second lien notes fair value as of March 31, 2020 $ 339,371 Change in fair value 78,539 Second lien notes fair value as of June 30, 2020 $ 417,910 Interest rate PIK 7,525 Principal prepayment (125,000) Change in fair value 20,737 Second lien notes fair value as of September 30, 2020 $ 321,172 See Note 12, Fair Value Measurements , for further discussion.

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate. During 2017, Option Care entered into interest rate caps that reduce the risk of increased interest payments due to interest rates rising. The hedges offset the risk of rising interest rates through 2020 on the first $250.0 million of the previous first lien term loan. The interest rate caps perfectly offset the terms of the interest rates associated with the variable interest rate previous first lien term loan. Option Care entered into the interest rate caps as a cash flow hedge for a notional amount of $1.9 million. In April 2019, Option Care terminated its interest rate caps. In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations following the Merger with BioScrip. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the first lien term loan interest payments indexed to one-month London Interbank Offered Rate (“LIBOR”) through August 2021. The remaining $13.9 million notional amount of the interest rate swap is not designated as a hedging instrument. The second interest rate swap of $400.0 million notional was effective in November 2019 and is designated as a cash flow hedge against the underlying interest rate on the second lien notes interest payments indexed to three-month LIBOR through November 2020. In May 2020, the Company elected to PIK the second lien note’s quarterly interest payment due in August 2020. Upon making the PIK election, the Company determined that the hedged interest payment would no longer occur, resulting in an ineffective hedge, so the Company discontinued hedge accounting on its $400.0 million notional interest rate swap. As a result, the Company reclassified accumulated comprehensive loss of $3.7 million to interest expense, net in the unaudited condensed consolidated statements of comprehensive income (loss). The gains and losses associated with the $400.0 million notional swap will be recognized in net income (loss) through interest expense until the swap expires in November 2020. See Note 10, Indebtedness , for further discussion of the PIK. In accordance with ASU 2017-12, Targeted Improvements to Accounting for Hedges , the Company has determined that the $911.1 million designated cash flow hedge is perfectly effective. The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2020 December 31, 2019 Interest rate swaps designated as cash flow hedges Accrued expenses and other current liabilities $ 15,229 $ 1,275 Interest rate swaps not designated as cash flow hedges Accrued expenses and other current liabilities 2,117 — Interest rate swaps designated as cash flow hedges Other non-current liabilities — 5,920 Interest rate swaps not designated as cash flow hedges Other non-current liabilities — 90 Total derivatives $ 17,346 $ 7,285 The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $400.0 million notional swap and the $13.9 million notional amount not designated as a hedging instrument are recognized in net income (loss) through interest expense. The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative 2020 2019 2020 2019 Interest rate caps designated as cash flow hedges $ — $ (398) $ — $ (1,103) Interest rate swaps designated as cash flow hedges 4,022 (7,883) (11,780) (7,883) Interest rate swaps that discontinued hedge accounting — — 3,746 — $ 4,022 $ (8,281) $ (8,034) $ (8,986) The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s unaudited condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative Income Statement Caption 2020 2019 2020 2019 Interest rate caps designated as cash flow hedges Interest expense $ — $ 269 $ — $ (125) Interest rate swaps designated as cash flow hedges Interest expense (4,152) 129 (8,604) 129 Interest rate swaps not designated as hedges Interest expense (41) (118) (32) (118) Interest rate swaps that discontinued hedge accounting Interest expense — — (3,746) — $ (4,193) $ 280 $ (12,382) $ (114) The Company expects to reclassify $13.9 million of total interest rate costs from accumulated other comprehensive loss against interest expense during the next 12 months.

FAIR VALUE MEASURMENTS

FAIR VALUE MEASURMENTS	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First lien term loan : The fair value of the first lien term loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the first lien term loan. Second lien notes : The fair value of the second lien notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the second lien notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments , for further discussion of the fair value of interest rate swaps. There were no other assets or liabilities measured at fair value at September 30, 2020 and December 31, 2019.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIESThe Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

STOCK-BASED INCENTIVE COMPENSAT

STOCK-BASED INCENTIVE COMPENSATION	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Incentive Compensation	STOCK-BASED INCENTIVE COMPENSATION Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. A total of 4,101,735 shares of common stock were initially authorized for issuance under the 2018 Plan. The Company had stock options and restricted stock outstanding related to the 2018 Plan as of September 30, 2020. As of September 30, 2020, the Company also had incentive units outstanding related to the HC I equity incentive plan, which was implemented in October 2015, for certain officers and employees of the Company. During the three and nine months ended September 30, 2020, total stock-based incentive compensation expense recognized by the Company related to these plans was $1.2 million and $2.6 million, respectively. During the three and nine months ended September 30, 2019, total stock-based incentive compensation expense recognized by the Company related to these plans was $2.7 million and $3.9 million, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY On January 3, 2020, the Company’s board of directors and HC I, the stockholder of a majority of the Company’s common stock, approved a reverse stock split of the Company’s issued and outstanding common stock on a one share for four share basis and appropriately amended the Company’s Third Amended and Restated Certificate of Incorporation to reflect the change. On February 3, 2020, the reverse stock split became effective. In connection with the reverse stock split, the Company changed its ticker symbol from “BIOS” to “OPCH” and transferred the Company’s common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The par value of the Company’s common stock remained unchanged as a result of the reverse stock split, resulting in a decrease to the aggregate par value of common stock and corresponding increase to paid-in capital in the Company’s unaudited condensed consolidated financial statements, which was retrospectively applied to all periods presented in the unaudited condensed consolidated financial statements. All common shares, warrants and stock awards presented in the unaudited condensed consolidated financial statements have been retrospectively adjusted for the reverse stock split. During the three months ended September 30, 2020, the Company completed a public offering of 20,700,000 shares of the Company’s common stock at a price of $12.50 per share, consisting of 10,000,000 shares of common stock issued and sold by the Company and 10,700,000 shares of common stock sold by HC I. Following the public offering, HC I holds approximately 70.6% of the common stock of the Company. The Company received net proceeds from the offering of $118.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company used the proceeds from the offering, along with additional cash on hand, to repay $125.0 million on the principal balance of its second lien notes outstanding. See Note 10, Indebtedness , for further discussion of the repayment of the second lien note. 2017 Warrants — During the three and nine months ended September 30, 2020, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2019, warrant holders did not elect to exercise any warrants to purchase shares of common stock. No warrants existed in 2019 prior to the Merger. As of September 30, 2020 and December 31, 2019, the remaining warrant holders are entitled to purchase 1.4 million shares of common stock, respectively. 2015 Warrants — During the three and nine months ended September 30, 2020, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2019, warrant holders did not elect to exercise any warrants to purchase shares of common stock. No warrants existed in 2019 prior to the Merger. As of September 30, 2020 and December 31, 2019, warrant holders are entitled to purchase 0.9 million shares of common stock, respectively. Home Solutions Restricted Stock — In conjunction with BioScrip’s 2016 acquisition of Home Solutions, Inc., 1.8 million restricted shares of common stock were issued, of which 0.8 million of these units vest upon the closing price of the Company’s common stock averaging at or above $16.00 per share over 20 consecutive trading days prior to December 31, 2019 and 1.0 million of these units vest upon the closing price of the Company’s common stock averaging at or above $20.00 per share over 20 consecutive trading days prior to December 31, 2019. The restricted stock expired on December 31, 2019. As discussed in Note 1, Nature of Operations and Presentation of Financial Statements , 7,048,357 common shares issued to HC I in conjunction with the Merger are held in escrow to prevent dilution related to the vesting of the Home Solutions restricted stock. In the event the Home Solutions restricted stock expires unvested, the 7,048,357 common shares held in escrow will be returned to the Company and canceled. As of September 30, 2020, the Home Solutions restricted stock remained in escrow pending final resolution of this matter.

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $0.8 million and $2.1 million for the three and nine months ended September 30, 2020, respectively. The Company recorded management fee income of $0.6 million and $1.8 million for the three and nine months ended September 30, 2019, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The Company had amounts due from its joint ventures of $1.8 million as of September 30, 2020. This receivable was included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. The Company also had amounts due to its joint ventures of $4.3 million as of December 31, 2019. This payable was included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS The Company has evaluated whether any subsequent events occurred since September 30, 2020, and noted the following subsequent event: In October 2020, the Company increased the borrowing capacity of its ABL facility from $150.0 million to $175.0 million, with net borrowings available of $165.4 million due to the Company’s $9.6 million of undrawn letters of credit issued and outstanding. In conjunction with the increase in borrowing capacity, the terms of the ABL facility were amended to call for monthly interest payments to be charged at the greater of 0.25% or LIBOR, plus 1.25% to 1.75%, depending on the historical excess availability as a percentage of the line cap, as defined in the ABL facility agreement. No other terms of the ABL facility were amended. The Company incurred bank and legal fees of approximately $0.1 million, which will be capitalized and amortized over the remaining term of the ABL facility.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2019 audited consolidated financial statements, including the notes thereto, as presented in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020.
Principles of Consolidation	Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. The BioScrip results have been included in the consolidated financial results since the Merger Date. All intercompany transactions and balances are eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Equity Method Investments	Equity Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2020 and December 31, 2019, the balance of the investments were $16.6 million and $17.0 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earning of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees are recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income (loss).
Concentrations of Business Risk	Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 16% and 15% for the three and nine months ended September 30, 2020. Revenue related to the Company’s largest payer was approximately 15% and 13% for the three and nine months ended September 30, 2019, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews at the end of that term. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented. For the three and nine months ended September 30, 2020, approximately 16% and 14%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2019, approximately 13% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of September 30, 2020 and December 31, 2019, respectively, approximately 13% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care.
Recent Accounting Pronouncements	Recently-Adopted Accounting Pronouncements — In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held. The Amendments in ASU 2016-13 eliminate the probable threshold for initial recognition of a credit loss in current GAAP and reflect an entity’s current estimate of all expected credit losses. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, and is to be applied using a modified retrospective transition method. The Company adopted the standard as of January 1, 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First lien term loan : The fair value of the first lien term loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the first lien term loan. Second lien notes : The fair value of the second lien notes is derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the second lien notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments , for further discussion of the fair value of interest rate swaps.

BUSINESS ACQUISITIONS (Tables)

BUSINESS ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Schedule of Consideration Exchanged	Under the acquisition method of accounting, the calculation of total consideration exchanged is as follows (in thousands): Amount Number of BioScrip common shares outstanding at time of the Merger (1) 129,181 Common shares issued to warrant and preferred stockholders at time of the Merger (1) 3,458 Total shares of BioScrip common stock outstanding at time of the Merger (1) 132,639 BioScrip share price as of August 6, 2019 $ 2.67 Fair value of common shares $ 354,146 Fair value of share-based instruments $ 32,898 Cash paid in conjunction with the Merger included in purchase consideration $ 714,957 Fair value of total consideration transferred $ 1,102,001 Less: cash acquired $ 14,787 Fair value of total consideration acquired, net of cash acquired $ 1,087,214 (1) These shares were not adjusted for the one share for four share reverse stock split effective on February 3, 2020. See Note 15, Stockholders’ Equity , for further discussion of the one share for four share reverse stock split.
Schedule of Acquired Identifiable Assets and Assumed Liabilities	The Company's allocation of consideration exchanged to the net tangible and intangible assets acquired and liabilities assumed, net of cash acquired, in the Merger is as follows (in thousands): Amount Accounts receivable, net (1) $ 96,532 Inventories (2) 19,683 Property and equipment, net (3) 48,732 Intangible assets, net (4) 193,245 Deferred tax assets, net of deferred tax liabilities (5) 26,731 Operating lease right-of-use asset (6) 22,378 Operating lease liability (6) (28,897) Accounts payable (7) (66,668) Other assumed liabilities, net of other acquired assets (7) (20,663) Total acquired identifiable assets and liabilities 291,073 Goodwill (8) 796,141 Total consideration transferred $ 1,087,214 (1) Management has valued accounts receivables based on the estimated future collectability of the receivables portfolio. (2) Inventories are stated at fair value as of the Merger Date. (3) The fair value of the property and equipment was determined based upon the best and highest use of the property with final values determined based upon an analysis of the cost, sales comparison, and income capitalization approaches for each property appraised. (4) The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,536 2 Patient referral sources 180,329 20 Licenses 380 1.5 Total intangible assets, net $ 193,245 18.8 The Company valued trademarks/names utilizing the relief of royalty method and patient referral sources utilizing the multi-period excess earnings method, a form of the income approach. (5) Net deferred tax assets represented the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases. (6) The fair value of the operating lease liability and corresponding right-of-use asset (current and long-term) was based on current market rates available to the Company. (7) Accounts payable as well as certain other current and non-current assets and liabilities are stated at fair value as of the Merger Date. (8) The Merger resulted in $796.1 million of goodwill, which is attributable to cost synergies resulting from procurement and operational efficiencies and elimination of duplicative administrative costs. The goodwill created in the Merger is not expected to be deductible for tax purposes.
Schedule of Allocation of Consideration to Intangible Assets Acquired	The allocation of consideration exchanged to intangible assets acquired is as follows (in thousands): Fair Value Weighted Average Estimated Life (in years) Trademarks/Names $ 12,536 2 Patient referral sources 180,329 20 Licenses 380 1.5 Total intangible assets, net $ 193,245 18.8

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Net Revenue Earned by Category of Payer	The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2020 and 2019 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Commercial payers $ 644,385 $ 525,927 $ 1,893,105 $ 1,373,481 Government payers 127,435 80,280 308,830 194,875 Patients 9,789 9,673 25,962 21,282 Net revenue $ 781,609 $ 615,880 $ 2,227,897 $ 1,589,638

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Share	The following table presents the Company’s basic earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) $ 1,663 $ (42,794) $ (25,915) $ (60,109) Denominator: Weighted average number of common shares outstanding 184,232 162,894 179,220 149,448 Earnings (loss) per common share: Earnings (loss) per common share, basic $ 0.01 $ (0.26) $ (0.14) $ (0.40) The following table presents the Company’s diluted earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator: Net income (loss) $ 1,663 $ (42,794) $ (25,915) $ (60,109) Denominator: Weighted average number of common shares outstanding 184,232 162,894 179,220 149,448 Effect of dilutive securities 590 — — — Weighted average number of common shares outstanding, diluted 184,822 162,894 179,220 149,448 Earnings (loss) per common share: Earnings (loss) per common share, diluted $ 0.01 $ (0.26) $ (0.14) $ (0.40)

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Maturities of Lease Liabilities, Operating	Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2020 $ 8,688 2021 22,799 2022 17,417 2023 13,698 2024 10,177 Thereafter 36,473 Total lease payments $ 109,252 Less: Interest 22,529 Present value of lease liabilities $ 86,723
Maturities of Lease Liabilities, Financing	Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2020 $ 8,688 2021 22,799 2022 17,417 2023 13,698 2024 10,177 Thereafter 36,473 Total lease payments $ 109,252 Less: Interest 22,529 Present value of lease liabilities $ 86,723

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment was as follows as of September 30, 2020 and December 31, 2019 (in thousands): September 30, 2020 December 31, 2019 Infusion pumps $ 33,368 $ 30,416 Equipment, furniture and other 49,931 51,454 Leasehold improvements 79,828 80,916 Computer software, purchased and internally developed 36,567 34,884 Assets under development 7,284 14,150 206,978 211,820 Less: accumulated depreciation 93,961 78,622 Property and equipment, net $ 113,017 $ 133,198 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Depreciation expense in cost of revenue $ 1,643 $ 1,384 $ 5,161 $ 2,855 Depreciation expense in operating expenses 7,814 8,522 28,546 18,849 Total depreciation expense $ 9,457 $ 9,906 $ 33,707 $ 21,704

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of the Carrying Amount of Goodwill	Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2020 (in thousands): Balance at December 31, 2019 $ 1,425,542 Purchase accounting adjustments 2,341 Balance at March 31, 2020 $ 1,427,883 Purchase accounting adjustments 727 Balance at June 30, 2020 $ 1,428,610 Changes — Balance at September 30, 2020 $ 1,428,610 Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2019 (in thousands): Balance at December 31, 2018 $ 632,469 Changes — Balance at March 31, 2019 $ 632,469 Changes — Balance at June 30, 2019 $ 632,469 Acquisitions 786,904 Balance at September 30, 2019 $ 1,419,373
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets	The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2020 and December 31, 2019 (in thousands): September 30, 2020 December 31, 2019 Gross intangible assets: Referral sources $ 438,121 $ 438,121 Trademarks/names 44,536 44,536 Other amortizable intangible assets 402 402 Total gross intangible assets 483,059 483,059 Accumulated amortization: Referral sources (103,947) (84,295) Trademarks/names (19,046) (12,748) Other amortizable intangible assets (300) (106) Total accumulated amortization (123,293) (97,149) Total intangible assets, net $ 359,766 $ 385,910

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Summary of Debt	Long-term debt consisted of the following as of September 30, 2020 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 918,063 (7,546) (20,506) 890,011 Second lien notes 294,781 (7,590) (5,116) 282,075 $ 1,212,844 $ (15,136) $ (25,622) 1,172,086 Less: current portion (9,250) Total long-term debt $ 1,162,836 Long-term debt consisted of the following as of December 31, 2019 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 925,000 (8,399) (22,825) 893,776 Second lien notes 412,256 (11,672) (7,864) 392,720 $ 1,337,256 $ (20,071) $ (30,689) 1,286,496 Less: current portion (9,250) Total long-term debt $ 1,277,246
Schedule of Long-term Debt Maturities	Long-term debt matures as follows (in thousands): Year Ending December 31, Minimum Payments 2020 $ 2,313 2021 9,250 2022 9,250 2023 9,250 2024 9,250 Thereafter 1,173,531 Total 1,212,844
Schedule of Estimated Fair Values of Debt Obligations	The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2020 (in thousands): Financial Instrument Carrying Value as of September 30, 2020 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First lien term loan $ 890,011 $ — $ 905,485 $ — Second lien notes 282,075 — — 321,172 Total debt instruments $ 1,172,086 $ — $ 905,485 $ 321,172 The following table sets forth the changes in Level 3 measurements for the three and nine months ended September 30, 2020 (in thousands): Level 3 Measurements Second lien notes fair value as of January 1, 2020 $ 411,119 Change in fair value (71,748) Second lien notes fair value as of March 31, 2020 $ 339,371 Change in fair value 78,539 Second lien notes fair value as of June 30, 2020 $ 417,910 Interest rate PIK 7,525 Principal prepayment (125,000) Change in fair value 20,737 Second lien notes fair value as of September 30, 2020 $ 321,172

DERIVATIVE INSTRUMENTS (Tables)

DERIVATIVE INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Amount and Location of Derivatives in the Balance Sheet	The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2020 December 31, 2019 Interest rate swaps designated as cash flow hedges Accrued expenses and other current liabilities $ 15,229 $ 1,275 Interest rate swaps not designated as cash flow hedges Accrued expenses and other current liabilities 2,117 — Interest rate swaps designated as cash flow hedges Other non-current liabilities — 5,920 Interest rate swaps not designated as cash flow hedges Other non-current liabilities — 90 Total derivatives $ 17,346 $ 7,285
Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)	The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative 2020 2019 2020 2019 Interest rate caps designated as cash flow hedges $ — $ (398) $ — $ (1,103) Interest rate swaps designated as cash flow hedges 4,022 (7,883) (11,780) (7,883) Interest rate swaps that discontinued hedge accounting — — 3,746 — $ 4,022 $ (8,281) $ (8,034) $ (8,986) The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s unaudited condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative Income Statement Caption 2020 2019 2020 2019 Interest rate caps designated as cash flow hedges Interest expense $ — $ 269 $ — $ (125) Interest rate swaps designated as cash flow hedges Interest expense (4,152) 129 (8,604) 129 Interest rate swaps not designated as hedges Interest expense (41) (118) (32) (118) Interest rate swaps that discontinued hedge accounting Interest expense — — (3,746) — $ (4,193) $ 280 $ (12,382) $ (114)

NATURE OF OPERATIONS AND PRES_2

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) $ / shares in Units, $ in Thousands	Aug. 06, 2019USD ($)$ / sharesshares	Sep. 30, 2020USD ($)pharmacy$ / shares	Dec. 31, 2019USD ($)$ / shares
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Principal amount of debt | $		$ 1,172,086	$ 1,286,496
OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Shares converted in merger (in shares) | shares	135,565,392
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Additional shares issued (in shares) | shares	7,048,357
Ownership retained by shareholders after merger	19.30%
Number of service locations | pharmacy		102
Preferred Stock and Certain Warrants | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Shares repurchased | $	$ 125,800
Preferred Stock and Certain Warrants | Common Stock | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Additional shares issued (in shares) | shares	864,603
HC Group Holdings I, LLC | OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Percentage of the combined company held	80.70%
Senior Notes | First Lien Term Loan
Business Acquisition [Line Items]
Principal amount of debt | $	$ 575,000
Legacy Health Systems
Business Acquisition [Line Items]
Ownership interest		50.00%

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Apr. 30, 2020
Concentration Risk [Line Items]
CARES Act grant						$ 11,700
Investments in equity-method investees	$ 16,600		$ 16,600		$ 17,000
Proportionate share of earnings in equity-method investees	800	$ 800	2,364	$ 2,018
Capital distribution received from investment	$ 2,300	$ 500	$ 2,800	$ 500
Revenue from Contract with Customer Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
Concentration risk	16.00%	15.00%	15.00%	13.00%
Contract term			2 years
Revenue from Contract with Customer Benchmark | Governmental Programs
Concentration Risk [Line Items]
Concentration risk	16.00%	13.00%	14.00%	12.00%
Accounts Receivable | Governmental Programs
Concentration Risk [Line Items]
Concentration risk	13.00%				12.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors
Concentration Risk [Line Items]
Concentration risk	71.00%	69.00%	72.00%	72.00%

BUSINESS ACQUISITIONS - Additio

BUSINESS ACQUISITIONS - Additional Information (Details) $ / shares in Units, $ in Millions	Feb. 03, 2020	Aug. 06, 2019USD ($)$ / shares
Business Acquisition [Line Items]
Stock split ratio	0.25
BioScrip
Business Acquisition [Line Items]
Share price (in dollars per share) | $ / shares		$ 2.67
Payment of shares in acquisition		$ 125.8
Success-based fees		14.1
Senior Notes | First Lien Term Loan | BioScrip
Business Acquisition [Line Items]
Payment in settlement of debt		$ 575

BUSINESS ACQUISITIONS - Conside

BUSINESS ACQUISITIONS - Consideration Exchanged (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 06, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 05, 2019
Business Acquisition [Line Items]
Number of BioScrip common shares outstanding at time of the merger (in shares)		186,757,753		176,591,907
Fair value of total consideration acquired, net of cash acquired		$ 0	$ 700,170
BioScrip
Business Acquisition [Line Items]
Number of BioScrip common shares outstanding at time of the merger (in shares)	132,639,000				129,181,000
Common shares issued to warrant and preferred stockholders at time of the merger (in shares)	3,458,000
BioScrip share price as of August 6, 2019 (in dollars per share)	$ 2.67
Fair value of common shares	$ 354,146
Fair value of share-based instruments	32,898
Cash paid in conjunction with the Merger included in purchase consideration	714,957
Fair value of total consideration transferred	1,102,001
Less: cash acquired	14,787
Fair value of total consideration acquired, net of cash acquired	$ 1,087,214

BUSINESS ACQUISITIONS - Acquire

BUSINESS ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Aug. 06, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill	$ 1,428,610	$ 1,428,610	$ 1,427,883	$ 1,425,542	$ 1,419,373		$ 632,469	$ 632,469	$ 632,469
BioScrip
Business Acquisition [Line Items]
Accounts receivable, net						$ 96,532
Inventories						19,683
Property and equipment, net						48,732
Intangible assets, net						193,245
Deferred tax assets, net of deferred tax liabilities						26,731
Operating lease right-of-use asset						22,378
Operating lease liability						(28,897)
Accounts payable						(66,668)
Other assumed liabilities, net of other acquired assets						(20,663)
Total acquired identifiable assets and liabilities						291,073
Goodwill						796,141
Total consideration transferred						$ 1,087,214

BUSINESS ACQUISITIONS - Consi_2

BUSINESS ACQUISITIONS - Consideration Allocated to Intangible Assets (Details) - BioScrip $ in Thousands	Aug. 06, 2019USD ($)
Business Acquisition [Line Items]
Total intangible assets, net	$ 193,245
Weighted Average Estimated Life (in years)	18 years 9 months 18 days
Trademarks/Names
Business Acquisition [Line Items]
Total intangible assets, net	$ 12,536
Weighted Average Estimated Life (in years)	2 years
Patient referral sources
Business Acquisition [Line Items]
Total intangible assets, net	$ 180,329
Weighted Average Estimated Life (in years)	20 years
Licenses
Business Acquisition [Line Items]
Total intangible assets, net	$ 380
Weighted Average Estimated Life (in years)	1 year 6 months

BUSINESS ACQUISITIONS - Pro For

BUSINESS ACQUISITIONS - Pro Forma Financial Information (Details) - BioScrip - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Business Acquisition [Line Items]
Net revenue	$ 690.4	$ 2,034.6
Net loss	$ 18.7	$ 54.2

REVENUE - Net Revenue Earned by

REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Net revenue	$ 781,609	$ 615,880	$ 2,227,897	$ 1,589,638
Commercial payers
Disaggregation of Revenue [Line Items]
Net revenue	644,385	525,927	1,893,105	1,373,481
Government payers
Disaggregation of Revenue [Line Items]
Net revenue	127,435	80,280	308,830	194,875
Patients
Disaggregation of Revenue [Line Items]
Net revenue	$ 9,789	$ 9,673	$ 25,962	$ 21,282

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 756	$ 3,576	$ 2,267	$ (3,269)
Effective tax rate	31.30%	(9.10%)	(9.60%)	5.20%
State net operating losses	$ 600		$ 600

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of Basic and Diluted Earnings (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net (loss) income	$ 1,663	$ (7,668)	$ (19,910)	$ (42,794)	$ (13,603)	$ (3,712)	$ (25,915)	$ (60,109)
Denominator:
Weighted average number of common shares outstanding (in shares)	184,232,000			162,894,000			179,220,000	149,448,000
Effect of dilutive securities (in shares)	590,000			0			0	0
Weighted average common shares outstanding, diluted (in shares)	184,822,000			162,894,000			179,220,000	149,448,000
Earnings (loss) per common share:
Earnings (loss) per share, basic (in dollars per share)	$ 0.01			$ (0.26)			$ (0.14)	$ (0.40)
Earnings (loss) per share, diluted (in dollars per share)	$ 0.01			$ (0.26)			$ (0.14)	$ (0.40)
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)				2,987,336			2,328,120	2,987,336
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)				657,846			424,878	657,846
Restricted Stock Award
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)				109,905			600,483	109,905

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 7.6	$ 7.4	$ 23	$ 21.5
Weighted-average remaining lease term, operating leases	6 years 9 months 18 days		6 years 9 months 18 days
Weighted-average discount rate, operating leases	5.30%		5.30%
Increase in operating lease right-of-use asset and lease liabilities	$ 20.1		$ 20.1

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2020USD ($)
Minimum Payments
Minimum Payments, Total lease payments, 2020	$ 8,688
Minimum Payments, Total lease payments, 2021	22,799
Minimum Payments, Total lease payments, 2022	17,417
Minimum Payments, Total lease payments, 2023	13,698
Minimum Payments, Total lease payments, 2024	10,177
Minimum Payments, Total lease payments, Thereafter	36,473
Minimum Payments, Total lease payments	109,252
Less: Interest	22,529
Present value of lease liabilities	$ 86,723

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 206,978		$ 206,978		$ 211,820
Less: accumulated depreciation	93,961		93,961		78,622
Property and equipment, net	113,017		113,017		133,198
Depreciation expense	9,457	$ 9,906	33,707	$ 21,704
Infusion pumps
Property, Plant and Equipment [Line Items]
Property and equipment, gross	33,368		33,368		30,416
Equipment, furniture and other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	49,931		49,931		51,454
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	79,828		79,828		80,916
Computer software, purchased and internally developed
Property, Plant and Equipment [Line Items]
Property and equipment, gross	36,567		36,567		34,884
Assets under development
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,284		7,284		$ 14,150
Depreciation expense in cost of revenue
Property, Plant and Equipment [Line Items]
Depreciation expense	1,643	1,384	5,161	2,855
Depreciation expense in operating expenses
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 7,814	$ 8,522	$ 28,546	$ 18,849

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Goodwill [Roll Forward]
Goodwill - net book value, begging of period	$ 1,428,610	$ 1,427,883	$ 1,425,542	$ 632,469	$ 632,469	$ 632,469
Purchase accounting adjustments and acquisitions	0	727	2,341	786,904	0	0
Goodwill - net book value, end of period	$ 1,428,610	$ 1,428,610	$ 1,427,883	$ 1,419,373	$ 632,469	$ 632,469

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	$ 483,059		$ 483,059		$ 483,059
Total accumulated amortization	(123,293)		(123,293)		(97,149)
Total intangible assets, net	359,766		359,766		385,910
Amortization expense for intangible assets	8,800	$ 7,500	26,300	$ 17,300
Referral sources
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	438,121		438,121		438,121
Total accumulated amortization	(103,947)		(103,947)		(84,295)
Trademarks/names
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	44,536		44,536		44,536
Total accumulated amortization	(19,046)		(19,046)		(12,748)
Other amortizable intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	402		402		402
Total accumulated amortization	$ (300)		$ (300)		$ (106)

INDEBTEDNESS - Summary of Debt

INDEBTEDNESS - Summary of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Principal Amount	$ 1,212,844	$ 1,337,256
Discount	(15,136)	(20,071)
Debt Issuance Costs	(25,622)	(30,689)
Total	1,172,086	1,286,496
Less: current portion	(9,250)	(9,250)
Total long-term debt	1,162,836	1,277,246
Senior Notes | First lien term loan
Debt Instrument [Line Items]
Principal Amount	918,063	925,000
Discount	(7,546)	(8,399)
Debt Issuance Costs	(20,506)	(22,825)
Total	890,011	893,776
Senior Notes | Second lien notes
Debt Instrument [Line Items]
Principal Amount	294,781	412,256
Discount	(7,590)	(11,672)
Debt Issuance Costs	(5,116)	(7,864)
Total	282,075	392,720
Senior Notes | ABL facility
Debt Instrument [Line Items]
Principal Amount	0	0
Discount	0	0
Debt Issuance Costs	0	0
Total	$ 0	$ 0

INDEBTEDNESS - Additional Infor

INDEBTEDNESS - Additional Information (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Paid-in-kind interest capitalized as principal				$ 7,525	$ 0
Repayment of debt				6,937	2,075
Loss on extinguishment of debt				8,349	$ 5,469
Common Stock | Public Offering
Debt Instrument [Line Items]
Proceeds from issuance of equity		$ 118,900
Credit Agreements, Entered Into 2019
Debt Instrument [Line Items]
Loss on extinguishment of debt		8,300
Prepayment penalty		2,500		2,500
Deferred financing fee		5,800		$ 5,800
Credit Agreements, Entered Into 2019 | Notes Payable
Debt Instrument [Line Items]
Repayment of debt		$ 125,000
First Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Effective rate on term loans at end of period		4.65%		4.65%		6.20%
Weighted average interest rate paid on term loans during period	6.67%	4.67%	6.06%	5.29%	6.20%
Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Senior Notes
Debt Instrument [Line Items]
Effective rate on term loans at end of period		9.00%		9.00%		10.66%
Weighted average interest rate paid on term loans during period	10.89%	9.51%	11.02%	10.17%	11.36%
Paid-in-kind interest capitalized as principal				$ 7,500
Additional interest rate charged		1.00%		1.00%

INDEBTEDNESS - Long Term Debt M

INDEBTEDNESS - Long Term Debt Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
2020	$ 2,313
2021	9,250
2022	9,250
2023	9,250
2024	9,250
Thereafter	1,173,531
Total	$ 1,212,844	$ 1,337,256

INDEBTEDNESS - Estimated Fair V

INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Interest rate PIK				$ 7,525	$ 0
Repayments of debt principal				(6,937)	$ (2,075)
Senior Notes
Debt Instrument [Line Items]
Total debt instruments	$ 1,172,086			1,172,086
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	1,172,086			1,172,086
Senior Notes | First lien term loan
Debt Instrument [Line Items]
Total debt instruments	890,011			890,011
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	890,011			890,011
Senior Notes | Second lien notes
Debt Instrument [Line Items]
Total debt instruments	282,075			282,075
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	282,075			282,075
Senior Notes | Markets for Identical Item (Level 1)
Debt Instrument [Line Items]
Total debt instruments	0			0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0			0
Senior Notes | Markets for Identical Item (Level 1) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments	0			0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0			0
Senior Notes | Markets for Identical Item (Level 1) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments	0			0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0			0
Senior Notes | Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments	905,485			905,485
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	905,485			905,485
Senior Notes | Significant Other Observable Inputs (Level 2) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments	905,485			905,485
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	905,485			905,485
Senior Notes | Significant Other Observable Inputs (Level 2) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments	0			0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0			0
Senior Notes | Significant Unobservable Inputs (Level 3)
Debt Instrument [Line Items]
Total debt instruments	321,172			321,172
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	321,172			321,172
Senior Notes | Significant Unobservable Inputs (Level 3) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments	0			0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, end of period	0			0
Senior Notes | Significant Unobservable Inputs (Level 3) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments	321,172	$ 417,910	$ 339,371	321,172
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Total debt instruments, beginning of period	417,910	339,371	411,119	411,119
Change in fair value	20,737	78,539	(71,748)
Interest rate PIK	7,525
Repayments of debt principal	(125,000)
Total debt instruments, end of period	$ 321,172	$ 417,910	$ 339,371	$ 321,172

DERIVATIVE INSTRUMENTS - Additi

DERIVATIVE INSTRUMENTS - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Nov. 06, 2019	Aug. 31, 2019	Dec. 31, 2017
Derivative [Line Items]
Total interest rate costs expected to reclassify during next 12 months		$ 13,900		$ 13,900
Interest Rate Cap | Interest expense
Derivative [Line Items]
Accumulated comprehensive loss reclassified		0	$ (269)	0	$ 125
Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative							$ 925,000
Interest Rate Swap | Interest expense
Derivative [Line Items]
Accumulated comprehensive loss reclassified	$ 3,700	$ 4,152	$ (129)	$ 8,604	$ (129)
Designated as Hedging Instrument | Senior Notes | First Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Cap
Derivative [Line Items]
Notional amount of derivative								$ 250,000
Designated as Hedging Instrument | Senior Notes | Second Lien Term Loan | Credit Agreements, Entered Into 2019 | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative						$ 400,000
Not Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative							13,900
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Cap
Derivative [Line Items]
Notional amount of derivative								$ 1,900
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap
Derivative [Line Items]
Notional amount of derivative							$ 911,100

DERIVATIVE INSTRUMENTS - Balanc

DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair value - Derivatives in liability position
Total derivatives	$ 17,346	$ 7,285
Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	15,229	1,275
Designated as Hedging Instrument | Other non-current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	0	5,920
Not Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	2,117	0
Not Designated as Hedging Instrument | Other non-current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	$ 0	$ 90

DERIVATIVE INSTRUMENTS - Pre-ta

DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized		$ 4,022	$ (8,281)	$ (8,034)	$ (8,986)
Total gain (loss) on derivatives		(4,193)	280	(12,382)	(114)
Interest Rate Cap
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized		0	(398)	0	(1,103)
Interest Rate Swap
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized		4,022	(7,883)	(11,780)	(7,883)
Interest rate swaps that discontinued hedge accounting		0	0	3,746	0
Interest expense | Interest Rate Cap
Derivative [Line Items]
Gain (loss) location of derivative instruments		0	269	0	(125)
Interest expense | Interest Rate Swap
Derivative [Line Items]
Gain (loss) location of derivative instruments	$ (3,700)	(4,152)	129	(8,604)	129
Gain (loss) location of derivative instruments not designated		(41)	(118)	(32)	(118)
Gain (loss) location of discontinued derivative instruments		$ 0	$ 0	$ (3,746)	$ 0

STOCK-BASED INCENTIVE COMPENS_2

STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	May 03, 2018
HC I Incentive Units
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense	$ 1.2	$ 2.7	$ 2.6	$ 3.9
The 2018 Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)					4,101,735

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Thousands	Feb. 03, 2020	Aug. 06, 2019shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019Days$ / sharesshares	Dec. 31, 2016shares	Aug. 05, 2019shares
Class of Warrant or Right [Line Items]
Stock split ratio	0.25
Repayment of debt | $				$ 6,937	$ 2,075
HC Group Holdings I, LLC
Class of Warrant or Right [Line Items]
Percentage of common stock			0.706
Credit Agreements, Entered Into 2019 | Notes Payable
Class of Warrant or Right [Line Items]
Repayment of debt | $			$ 125,000
Common Stock | Public Offering
Class of Warrant or Right [Line Items]
Additional shares issued (in shares)			20,700,000
Shares issued, price per share (in usd per share) | $ / shares			$ 12.50	$ 12.50
Proceeds from issuance of equity | $			$ 118,900
Common Stock | Public Offering | Option Care Health, Inc
Class of Warrant or Right [Line Items]
Additional shares issued (in shares)			10,000,000
Common Stock | Public Offering | HC Group Holdings I, LLC
Class of Warrant or Right [Line Items]
Additional shares issued (in shares)			10,700,000
Common Stock | 2017 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)			1,400,000	1,400,000		1,400,000		0
Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)			900,000	900,000		900,000		0
OptionCare Enterprises, Inc.
Class of Warrant or Right [Line Items]
Additional shares issued (in shares)		7,048,357
Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)							1,800,000
Tranche One | Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)						800,000
Stock price threshold (in dollars per share) | $ / shares						$ 16
Consecutive trading days threshold | Days						20
Tranche Two | Restricted Stock Units (RSUs) | Home Solutions
Class of Warrant or Right [Line Items]
Shares issued pursuant to acquisition (in shares)						1,000,000
Stock price threshold (in dollars per share) | $ / shares						$ 20
Consecutive trading days threshold | Days						20

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Details) - Joint Venture - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Management fee income	$ 0.8	$ 0.6	$ 2.1	$ 1.8
Due from joint venture	$ 1.8		$ 1.8
Due to joint ventures					$ 4.3

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) - ABL facility - Senior Notes - Credit Agreements, Entered Into 2019 - USD ($)	1 Months Ended
	Oct. 31, 2020	Aug. 06, 2019
Subsequent Event [Line Items]
Debt instrument, face amount		$ 150,000,000
Subsequent Event
Subsequent Event [Line Items]
Debt instrument, face amount	$ 175,000,000
Remaining borrowing amount available	165,400,000
Letters of credit outstanding	9,600,000
Legal fees	$ 100,000
Subsequent Event | LIBOR
Subsequent Event [Line Items]
Debt instrument, basis spread	0.25%
Subsequent Event | Base Rate | Minimum
Subsequent Event [Line Items]
Debt instrument, basis spread	1.25%
Subsequent Event | Base Rate | Maximum
Subsequent Event [Line Items]
Debt instrument, basis spread	1.75%